Organization
Cytokinetics
12 clinical trials
Clinical trial
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic CardiomyopathyStatus: Completed, Estimated PCD: 2023-02-28
Clinical trial
A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract ObstructionStatus: Completed, Estimated PCD: 2023-12-01
Clinical trial
A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment of Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)Status: , Estimated PCD: 2026-03-01
Clinical trial
A Randomized, 2-Part, Single-Dose, Crossover Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval in Healthy ParticipantsStatus: Completed, Estimated PCD: 2023-11-14
Clinical trial
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic CardiomyopathyStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3828136 in Healthy ParticipantsStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)Status: Terminated, Estimated PCD: 2023-03-31
Clinical trial
A Phase 1, Double-blind, Randomized, Placebo-controlled, Multi-part, Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult ParticipantsStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)Status: Terminated, Estimated PCD: 2023-03-31
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise ToleranceStatus: Completed, Estimated PCD: 2021-11-08
Clinical trial
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic CardiomyopathyStatus: Not yet recruiting, Estimated PCD: 2028-12-01